Sandip Kapadia - 26 Jan 2026 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Christian Ulrich, Attorney-in-Fact
Issuer symbol
HRMY
Transactions as of
26 Jan 2026
Net transactions value
-$139,171
Form type
4
Filing time
28 Jan 2026, 20:19:26 UTC
Previous filing
26 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kapadia Sandip CHIEF FINANCIAL OFFICER C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING /s/ Christian Ulrich, Attorney-in-Fact 28 Jan 2026 0001677141

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Sale $139,171 -3,746 -13% $37.15 24,521 26 Jan 2026 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.57 to $37.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reporting person's previous Form 4 filed on January 26, 2026 inadvertently misstated the number of shares of common stock beneficially owned following the transactions reported therein, and that the number has been corrected in the current filing.